Prognostic markers associated with disulfide death show that patients in the high-risk group have a more complex tumor immune microenvironment, making them more susceptible to tumor immune escape during immunotherapy, while patients in the low-risk group have better prognosis and response to immune therapy, especially to anti-PD1 and anti-CTLA-4 inhibitors [144]. This evidence concerns the gene CTLA4 and neoplasm.